Alcon Introduces Clareon® TruPlus IOLs at ASCRS 2026, Expanding Its Advanced Cataract Surgery Portfolio
Alcon, a global leader in eye care innovation, has officially launched its latest intraocular lens (IOL), Clareon® TruPlus, in the United States during the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) 2026 in Washington, D.C. This new offering represents a significant advancement in monofocal and toric IOL design, aimed at improving patient outcomes while maintaining the trusted visual performance surgeons expect.
The Clareon TruPlus IOL introduces an enhanced design that extends depth of focus without compromising high-quality distance vision—an essential balance long sought by cataract surgeons. With this launch, Alcon continues to strengthen its leadership in ophthalmic innovation and broaden its already robust Clareon lens portfolio.
A New Standard in Monofocal IOL Design
Traditional monofocal IOLs have long been valued for their ability to deliver excellent distance vision. However, they typically offer limited intermediate vision, which can restrict everyday visual functionality. The Clareon TruPlus IOL addresses this limitation by incorporating an advanced optical design that slightly extends depth of focus, enabling improved performance at intermediate distances while preserving crisp distance clarity.
This innovation is particularly important for modern patients, whose lifestyles increasingly demand seamless vision across various distances—from driving to working on digital devices.
According to Alcon, TruPlus was specifically developed in response to surgeon feedback. Many clinicians expressed a desire for an “enhanced monofocal” lens that could deliver more functional vision without introducing the trade-offs often associated with multifocal or extended depth of focus (EDOF) lenses, such as halos or glare.
Key Performance Advantages of TruPlus
Bench testing and comparative analyses highlight several differentiating features that position Clareon TruPlus as a strong competitor in the IOL market:
Improved Intermediate Vision
TruPlus demonstrates a 3.5-letter improvement in simulated visual acuity at -1.5 diopters (approximately 66 cm) compared to the standard Clareon monofocal lens. This translates into better intermediate vision, which is critical for tasks like reading a computer screen or viewing a car dashboard.
Superior Distance Image Quality
The lens maintains exceptional distance image quality across a wide range of pupil sizes and lighting conditions. Notably, it has shown higher distance image quality than TECNIS Eyhance, a leading competitor in the enhanced monofocal category.
Compliance with International Standards
TruPlus exceeds the ISO upper requirement for distance image quality, reinforcing its reliability and performance consistency.
Reduced Visual Disturbances
Another important advantage is its lower glare and halo profile compared to competing lenses. This is particularly beneficial for patients sensitive to nighttime visual disturbances, such as those who drive frequently after dark.
The Science Behind TruPlus: Opti-Balance™ Technology
At the core of the Clareon TruPlus design is Alcon’s proprietary Opti-Balance™ Technology. This innovation is embedded in the central portion of the lens and works by redistributing light energy to subtly extend the depth of focus.
Unlike multifocal lenses that split light into multiple focal points—often causing unwanted visual side effects—Opti-Balance Technology enhances focus in a more controlled and natural way. The result is a wider refractive landing zone, allowing patients to achieve functional vision across distances without sacrificing image quality.
This design philosophy reflects a growing trend in ophthalmology: delivering incremental visual improvements while maintaining the simplicity and predictability of monofocal lenses.
Surgeon Perspective: Meeting Unmet Needs
Dr. Terry Kim, Chief Medical Officer at Alcon, emphasized the clinical motivation behind TruPlus:
Cataract surgeons naturally want to offer patients a little more—without trade-offs. TruPlus was developed to meet that need, delivering enhanced depth of focus while preserving the exceptional clarity and stability of the Clareon platform.”
This sentiment highlights a key shift in cataract surgery—from simply restoring vision to optimizing visual performance and quality of life.
Expanding the Clareon Portfolio
The introduction of TruPlus further strengthens Alcon’s Clareon family of IOLs, which already includes several widely used and clinically validated options:
- Clareon Monofocal – A leading standard monofocal lens known for clarity and stability
- Vivity® – An extended depth of focus (EDOF) IOL offering broader visual range
- PanOptix® and PanOptix® Pro – Among the most widely implanted trifocal IOLs globally
With over 175 million IOLs implanted worldwide, Alcon has established itself as a dominant force in cataract surgery. TruPlus adds a new dimension to this portfolio by filling the gap between traditional monofocal and more complex premium lenses.
The company has also announced plans to expand the availability of TruPlus into additional global markets later this year.
Strong Scientific Presence at ASCRS 2026
Beyond the TruPlus launch, Alcon is showcasing its broader commitment to innovation through a significant scientific presence at ASCRS 2026. The company is supporting more than 60 scientific presentations, featuring both internal research and independent clinical studies.
These presentations span multiple areas of ophthalmology, including cataract surgery, refractive procedures, and ocular surface care.
Highlights from Featured Studies
Some of the notable research being presented includes:
- Novel Phacoemulsification Systems
Early clinical experiences and intraoperative analyses using advanced imaging technologies like OCT are being showcased, highlighting improvements in surgical precision and anterior chamber stability. - Advancements in LASIK Technology
Studies comparing ray tracing-guided LASIK versus traditional wavefront-optimized approaches suggest improved functional outcomes and personalized treatment benefits. - Dry Eye Innovations
Phase 3 results for Acoltremon, a TRPM8 agonist, demonstrate promising outcomes in tear production and lipid layer enhancement—key factors in managing dry eye disease. - IOL Comparative Studies
Independent investigations evaluating enhanced monofocal lenses provide insights into visual disturbances and optical performance, further validating the clinical positioning of TruPlus.
Educational Engagement and Peer Collaboration
In addition to scientific presentations, Alcon is actively fostering knowledge exchange through peer-to-peer educational symposia held during the ASCRS meeting at the Walter E. Washington Convention Center.
Featured Symposia Topics
- Transforming In-Clinic Care
This session focuses on evolving strategies in managing glaucoma and dry age-related macular degeneration (AMD), emphasizing practical, real-world applications. - The Perfect Pairing: Cataract Surgery Success
A discussion centered on optimizing surgical outcomes through advanced technologies and best practices in modern cataract procedures.
These sessions bring together leading ophthalmologists to share experiences, discuss emerging trends, and translate innovation into everyday clinical practice.
Hands-On Innovation at the Exhibition Booth
Attendees at ASCRS 2026 can also explore Alcon’s latest technologies through live demonstrations and interactive experiences at the company’s exhibition booth (#943).
These hands-on opportunities allow surgeons to:
- Experience new surgical systems
- Evaluate lens technologies firsthand
- Engage directly with experts and peers
Such initiatives underscore Alcon’s commitment not only to innovation but also to education and collaboration within the ophthalmic community.
Looking Ahead: The Future of Cataract Surgery
The launch of Clareon TruPlus represents more than just a new product—it signals a broader evolution in cataract care. As patient expectations rise, the demand for solutions that deliver both quality and versatility continues to grow.
By focusing on enhanced monofocal designs, Alcon is addressing a critical gap in the market—offering improved functional vision without the complexity or side effects of premium multifocal lenses.
With continued investment in research, technology, and surgeon education, Alcon is well-positioned to shape the future of vision care and help millions of patients worldwide achieve better visual outcomes.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.
About Clareon® TruPlus IOLs
The Clareon Family of Lenses are artificial lenses implanted in the eye of adult patients following cataract surgery. The Clareon® TruPlus IOLs are designed to allow for clear distance vision. However, you will likely still need glasses for reading and for distance vision, particularly if you already have astigmatism. The Clareon® TruPlus Toric IOLs are designed to correct pre-existing corneal astigmatism, which is the inability of the eye to focus clearly at any distance because of different curvatures on the cornea, and provide distance vision. These IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions.
